The market had been waiting for clinical validation, not a transaction benchmark. Opakalim’s RISE3 topline data were already expected in the second half of 2026, but the filing introduces no published consensus valuation or deal expectation to beat. Against that backdrop, the cleanest read is that Biohaven has converted a still-clinical-stage asset into substantial near-term capital before the pivotal readout. 〔0〕
| Deal economics | Amount / terms |
|---|---|
| Cash consideration | $400 million |
| Payable at closing | $350 million |
| Additional cash payment | $50 million in 2027 |
| Development and regulatory milestones to Biohaven | Up to $150 million |
| Knopp and future Kv7 obligations assumed by SK | Up to $245 million |
| Total headline payments and assumed obligations | Up to $795 million |
| U.S. opakalim royalties | Mid-teens to low twenties |
| Ex-U.S. opakalim royalties | Mid-single digits |
The immediate financial impact is the strongest part of the announcement. Biohaven receives $350 million at closing and another $50 million in 2027, while SK takes on specified future Kv7 program costs and up to $245 million of legacy and pipeline obligations. This is meaningful non-dilutive funding and reduces the amount of capital Biohaven must commit to development and eventual commercialization.
The headline $795 million materially overstates the near-term cash value. Only $400 million is cash consideration, while the $150 million is contingent on development and regulatory milestones and the $245 million is assumed obligations that otherwise would have remained with Biohaven. The recurring royalties preserve upside, but they are tied to eventual approval and commercial sales rather than current revenue. The economics are therefore a substantial de-risking payment, not a realized $795 million cash exit.
SK’s involvement improves the commercialization path but transfers away full ownership economics. SK receives exclusive worldwide rights to opakalim and the broader Kv7 platform, while bringing an existing epilepsy commercial infrastructure and responsibility for development and commercialization in major markets. That lowers Biohaven’s future operating burden, but Biohaven is monetizing before RISE3 results, so the company gives up worldwide control and much of the potential upside if the pivotal data and launch are highly successful.
Net read: a meaningful positive strategic surprise, with the clinical catalyst still intact. The agreement strengthens Biohaven’s balance sheet, lowers future Kv7 spending, and validates partner interest in opakalim before the key data event. Closing remains conditional on antitrust clearance and customary conditions. 〔1〕 The next decisive update is RISE3 topline data, expected in the second half of 2026.
Read the original 8-K on SEC EDGAR ↗